Bhutan vs Lao People's Democratic Republic: Access to anti-retroviral drugs, male
Bhutan
62.0%
in 2024
Lao People's Democratic Republic
61.0%
in 2024
Bhutan rank
94th
Lao People's Democratic Republic rank
97th
Access to anti-retroviral drugs, male over time
- Bhutan
- Lao People's Democratic Republic
How they compare
Bhutan currently reports 62.0% against 61.0% in Lao People's Democratic Republic, a difference of 1.0%.
The two have swapped places 1 time across 24 shared years of data; in 2000 it was Lao People's Democratic Republic ahead.
Bhutan ranks 94th and Lao People's Democratic Republic ranks 97th of 141 countries.
Across the 3 decades both report, Bhutan averaged higher in 2 and Lao People's Democratic Republic in 1.
Head to head by decade
| Decade | Bhutan | Lao People's Democratic Republic | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.2% | 5.8% | 2.6% | Lao People's Democratic Republic |
| 2010s | 33.6% | 25.4% | 8.2% | Bhutan |
| 2020s | 58.0% | 51.4% | 6.6% | Bhutan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Bhutan or Lao People's Democratic Republic?
- Bhutan, at 62.0% against 61.0% in Lao People's Democratic Republic as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Bhutan and Lao People's Democratic Republic?
- 1.0%, with Bhutan ahead.
- How many years of comparable data are there for Bhutan and Lao People's Democratic Republic?
- 24 years are reported by both, from 2000 to 2024.
- How do Bhutan and Lao People's Democratic Republic rank globally for access to anti-retroviral drugs, male?
- Bhutan ranks 94th and Lao People's Democratic Republic ranks 97th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.